Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing.

Saved in:
Bibliographic Details
Title: Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing.
Authors: Hu X; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Xu Y; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Wang Z; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Yang L; Department of Oncology, Yueyang People's Hospital of Hunan Normal University, Yueyang, China., Zheng B; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Sun F; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Liu D; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Shi B; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Zheng H; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Liu X; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Yu L; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China., Zhang S; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Radiology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China., Yan Y; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Yan W; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. yanwj@fudan.edu.cn.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. yanwj@fudan.edu.cn., Sun Y; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Chen Y; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. chenyong@fudan.edu.cn.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. chenyong@fudan.edu.cn., Wang C; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. cmwang_gr@fudan.edu.cn.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. cmwang_gr@fudan.edu.cn.
Source: Molecular cancer [Mol Cancer] 2026 Apr 27; Vol. 25 (1). Date of Electronic Publication: 2026 Apr 27.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-4598
DOI:10.1186/s12943-026-02675-w